- Home
- FT vs SKYE Comparison
FT vs SKYE Comparison
Compare FT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- SKYE
- Stock Information
- Founded
- FT 1988
- SKYE 2012
- Country
- FT United States
- SKYE United States
- Employees
- FT N/A
- SKYE N/A
- Industry
- FT Trusts Except Educational Religious and Charitable
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- FT Finance
- SKYE Health Care
- Exchange
- FT Nasdaq
- SKYE Nasdaq
- Market Cap
- FT 171.4M
- SKYE 172.9M
- IPO Year
- FT N/A
- SKYE N/A
- Fundamental
- Price
- FT $7.52
- SKYE $5.24
- Analyst Decision
- FT
- SKYE Strong Buy
- Analyst Count
- FT 0
- SKYE 5
- Target Price
- FT N/A
- SKYE $18.40
- AVG Volume (30 Days)
- FT 63.0K
- SKYE 142.7K
- Earning Date
- FT 01-01-0001
- SKYE 11-09-2024
- Dividend Yield
- FT 7.85%
- SKYE N/A
- EPS Growth
- FT N/A
- SKYE N/A
- EPS
- FT N/A
- SKYE N/A
- Revenue
- FT N/A
- SKYE N/A
- Revenue This Year
- FT N/A
- SKYE N/A
- Revenue Next Year
- FT N/A
- SKYE N/A
- P/E Ratio
- FT N/A
- SKYE N/A
- Revenue Growth
- FT N/A
- SKYE N/A
- 52 Week Low
- FT $5.97
- SKYE $1.44
- 52 Week High
- FT $7.23
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- FT 79.01
- SKYE 42.33
- Support Level
- FT $7.31
- SKYE $5.71
- Resistance Level
- FT $7.33
- SKYE $7.11
- Average True Range (ATR)
- FT 0.06
- SKYE 0.60
- MACD
- FT 0.01
- SKYE -0.08
- Stochastic Oscillator
- FT 84.87
- SKYE 10.00
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.